These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22526138)

  • 41. The use of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis in Lebanon.
    Uthman I; Mroueh K; Arayssi T; Nasr F; Masri AF
    Semin Arthritis Rheum; 2004 Jun; 33(6):422-3. PubMed ID: 15260002
    [No Abstract]   [Full Text] [Related]  

  • 42. Differential drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Sidiropoulos PI; Boumpas DT
    Ann Rheum Dis; 2006 Jun; 65(6):701-3. PubMed ID: 16699049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.
    Couriel DR; Hicks K; Giralt S; Champlin RE
    Curr Opin Oncol; 2000 Nov; 12(6):582-7. PubMed ID: 11085458
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treating rheumatoid arthritis with tumour necrosis factor alpha blockade.
    Emery P; Buch M
    BMJ; 2002 Feb; 324(7333):312-3. PubMed ID: 11834544
    [No Abstract]   [Full Text] [Related]  

  • 45. [The importance of biologicals in the treatment of SoJIA].
    Dückers G; Niehues T
    Z Rheumatol; 2010 Aug; 69(6):505-15. PubMed ID: 20668866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged efficacy of infliximab for refractory adult-onset Still's disease.
    Dilhuydy MS; Vatan R; Etienne G; Longy-Boursier M; Mercié P
    Clin Exp Rheumatol; 2005; 23(1):121-2. PubMed ID: 15789901
    [No Abstract]   [Full Text] [Related]  

  • 47. Tumor necrosis factor inhibitors and cancer in juvenile idiopathic arthritis: disentangling the web.
    Onel KB; Onel K
    Arthritis Rheum; 2012 Apr; 64(4):966-9. PubMed ID: 22327954
    [No Abstract]   [Full Text] [Related]  

  • 48. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
    Harriman G; Harper LK; Schaible TF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975
    [No Abstract]   [Full Text] [Related]  

  • 49. [Malignancy and tumor necrosis factor inhibitors in juvenile idiopathic arthritis].
    Horneff G
    Z Rheumatol; 2010 Aug; 69(6):516-26. PubMed ID: 20532787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
    Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
    Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis.
    Inoue K; Takano H; Yanagisawa R; Yoshikawa T
    Chest; 2003 Jul; 124(1):413-4; author reply 414. PubMed ID: 12853558
    [No Abstract]   [Full Text] [Related]  

  • 52. Infliximab treatment of rheumatoid arthritis.
    Maini SR
    Rheum Dis Clin North Am; 2004 May; 30(2):329-47, vii. PubMed ID: 15172044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic advancements in juvenile idiopathic arthritis.
    Kessler EA; Becker ML
    Best Pract Res Clin Rheumatol; 2014 Apr; 28(2):293-313. PubMed ID: 24974064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease.
    Sharma SM; Ramanan AV; Riley P; Dick AD
    Ann Rheum Dis; 2007 Jun; 66(6):840-1. PubMed ID: 17170050
    [No Abstract]   [Full Text] [Related]  

  • 55. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
    Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
    Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Verhoeven AC; Boers M
    Ned Tijdschr Geneeskd; 2001 Nov; 145(47):2294-5. PubMed ID: 11760611
    [No Abstract]   [Full Text] [Related]  

  • 57. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases.
    Kalden JR
    Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856
    [No Abstract]   [Full Text] [Related]  

  • 58. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 59. How many patients are eligible for anti-TNF therapy in the UK?
    Douglas K; Bowman SJ
    Rheumatology (Oxford); 2001 Dec; 40(12):1416. PubMed ID: 11752515
    [No Abstract]   [Full Text] [Related]  

  • 60. Spectacular evolution of reactive arthritis after early treatment with infliximab.
    Thomas-Pohl M; Tissot A; Banal F; Lechevalier D
    Joint Bone Spine; 2012 Oct; 79(5):524. PubMed ID: 22542050
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.